Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Phase IIa Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CBT-001 Ophthalmic Solution in Patients With Primary or Recurrent Pterygium

Ophthalmology Science(2024)10.1016/j.xops.2024.100502Source: DataRank Database

A Phase IIa Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CBT-001 Ophthalmic Solution in Patients With Primary or Recurrent Pterygium is a research paper published in Ophthalmology Science (2024). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.34)OA: goldTopics (18)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Kenneth Sall ORCID,John Hovanesian ORCID,Damien F. Goldberg,Olivia L Lee,Rong Yang ORCID

Live enrichment

PubMed:38883924 PMC:PMC11179250 OpenAlex:https://openalex.org/W4392381888

National Institutes of Health

Grant: 1R44EY028784-01

A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Pterygium Patients

National Eye Institute

FWCI

0.34

Citation Percentile

0.6%

Citation Trend

2026

goldLicense: cc-by

journalhttp://www.ophthalmologyscience.org/article/S2666914524000381/pdf

publisherhttp://www.ophthalmologyscience.org/article/S2666914524000381/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2666914524000381?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666914524000381?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.xops.2024.100502

Fields of Study

Corneal Surgery and TreatmentsFibroblast Growth Factor ResearchOcular Surface and Contact Lens03 medical and health sciences0302 clinical medicine

Keywords

MedicinePharmacokineticsPterygiumMulticenter studyRandomized controlled trialPhase (matter)OphthalmologyInternal medicineCorneaAngiogenesisTyrosine kinase inhibitorVascular Endothelial Growth FactorOriginal Article

Sustainable Development Goals

SDG 0: Good health and well-being